imaging
Convergent Therapeutics, Point Biopharma Pair Antibody, Radioligand Therapy in Prostate Cancer Study
The companies will enroll up to 33 PSMA-positive, advanced castration-resistant prostate cancer patients in a Phase I/II study of CONV 01-alpha and PNT2002.
The autologous CAR T-cell therapy P-PSMA-101 demonstrated anti-tumor activity in nine metastatic castrate-resistant prostate cancer patients based on PSA levels.
Perspectum Launches Study of Digital Pathology, WGS to Guide Liver Cancer Treatment
The firm will use its Hepatica imaging test with whole-genome sequencing to assess whether these integrated data can inform clinical decision-making.
Sophia Genetics Files for $100M IPO, Inks Cancer Data Deal With GE Healthcare
Sophia, which will trade on the Nasdaq, seeks to raise $100 million in an IPO, and separately announced a partnership with GE Healthcare.
Clovis Oncology Begins Study of FAP-2286 Targeted Imaging Agent, Radionuclide Therapy
The Phase I/II LuMIERE study is enrolling patients with different types of tumors at the O'Neal Comprehensive Cancer Center in Alabama.
Jan 10, 2020
May 30, 2019
Mar 25, 2019